58.80Open58.80Pre Close0 Volume52 Open Interest200.00Strike Price0.00Turnover131.18%IV5.44%PremiumJan 17, 2025Expiry Date45.44Intrinsic Value100Multiplier25DDays to Expiry13.36Extrinsic Value100Contract SizeAmericanOptions Type0.7806Delta0.0035Gamma4.17Leverage Ratio-0.5145Theta0.0921Rho3.26Eff Leverage0.1911Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet